Mechanisms of bradykinin-induced glucagon release in clonal α-cells In-R1-G9: involvement of Ca2+-dependent and -independent pathways

S Yibchok-anun,H Cheng,E.A Abu-Basha,J Ding,M Ioudina,W.H Hsu
DOI: https://doi.org/10.1016/S0303-7207(02)00115-6
IF: 4.369
2002-01-01
Molecular and Cellular Endocrinology
Abstract:The mechanisms by which bradykinin (BK) increases glucagon release were investigated. BK (0.1–10 μM) increased [Ca2+]i and glucagon release in clonal α-cells In-R1-G9. BK-induced glucagon release was lower in the absence than in the presence of extracellular Ca2+, but it still increased glucagon release while [Ca2+]i was stringently deprived. Depletion of intracellular Ca2+ store with thapsigargin abolished both the BK-induced Ca2+ peak and sustained plateau. Microinjection of heparin abolished BK-induced Ca2+ release. Pertussis toxin (PTX) did not block BK-induced [Ca2+]i increase or glucagon release. U-73122 (8 μM), a phospholipase C (PLC) inhibitor, abolished BK-induced increases in [Ca2+]i, but only reduced BK-induced glucagon release by 40%. A phospholipase D (PLD) inhibitor zLYCK reduced BK-induced glucagon release by 60%. The combination of U-73122 and zLYCK abolished BK-induced glucagon release. Both SK&F 96365, a receptor-operated Ca2+ channel (ROC) blocker and nimodipine, an L-type Ca2+ channel blocker, reduced BK-induced [Ca2+]i increase and glucagon release. These findings suggest that BK increase glucagon release through a PTX-insensitive G protein and both Ca2+-dependent and -independent pathways. The Ca2+-dependent pathway is attributable to PLC activation. PLC catalyzes IP3 formation, inducing Ca2+ release from the endoplasmic reticulum, which, in turn, triggers Ca2+ influx via both ROCs and L-type channels. PLD activation may be involved in Ca2+-dependent and/or -independent pathway.
What problem does this paper attempt to address?